Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

567 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High Incidence of SARS-CoV-2 Variant of Concern Breakthrough Infections Despite Residual Humoral and Cellular Immunity Induced by BNT162b2 Vaccination in Healthcare Workers: A Long-Term Follow-Up Study in Belgium.
Calcoen B, Callewaert N, Vandenbulcke A, Kerstens W, Imbrechts M, Vercruysse T, Dallmeier K, Van Weyenbergh J, Maes P, Bossuyt X, Zapf D, Dieckmann K, Callebaut K, Thibaut HJ, Vanhoorelbeke K, De Meyer SF, Maes W, Geukens N. Calcoen B, et al. Among authors: dieckmann k. Viruses. 2022 Jun 9;14(6):1257. doi: 10.3390/v14061257. Viruses. 2022. PMID: 35746728 Free PMC article. Clinical Trial.
Comparison of Two Commercially Available Interferon-γ Release Assays for T-Cell-Mediated Immunity and Evaluation of Humoral Immunity against SARS-CoV-2 in Healthcare Workers.
Lochmanová A, Martinek J, Tomášková H, Zelená H, Dieckmann K, Grage-Griebenow E, Ježo E, Janošek J. Lochmanová A, et al. Among authors: dieckmann k. Diagnostics (Basel). 2023 Feb 8;13(4):637. doi: 10.3390/diagnostics13040637. Diagnostics (Basel). 2023. PMID: 36832126 Free PMC article.
Alternative lengthening of telomere-based immortalization renders H3G34R -mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens.
Laemmerer A, Lehmann C, Mayr L, Bruckner K, Gabler L, Senfter D, Meyer P, Balber T, Pirker C, Jaunecker CN, Kirchhofer D, Vician P, Griesser M, Spiegl-Kreinecker S, Schmook MT, Traub-Weidinger T, Kuess P, Eckert F, Federico A, Madlener S, Stepien N, Robl B, Baumgartner A, Hainfellner JA, Dieckmann K, Dorfer C, Roessler K, Corsini NS, Holzmann K, Schmidt WM, Peyrl A, Azizi AA, Haberler C, Beck A, Pfister SM, Schueler J, Loetsch-Gojo D, Knoblich JA, Berger W, Gojo J. Laemmerer A, et al. Among authors: dieckmann k. Neuro Oncol. 2024 Nov 18:noae228. doi: 10.1093/neuonc/noae228. Online ahead of print. Neuro Oncol. 2024. PMID: 39556024
Glioblastoma in the real-world setting: patterns of care and outcome in the Austrian population.
Hainfellner A, Borkovec M, Seebrecht L, Neuhauser M, Roetzer-Pejrimovsky T, Greutter L, Surböck B, Hager-Seifert A, Gorka-Vom Hof D, Urbanic-Purkart T, Stultschnig M, Cijan C, Würtz F, Calabek-Wohinz B, Pichler J, Höllmüller I, Leibetseder A, Weis S, Kleindienst W, Seiberl M, Bieler L, Hecker C, Schwartz C, Iglseder S, Heugenhauser J, Nowosielski M, Thomé C, Moser P, Hoffermann M, Loibnegger K, Dieckmann K, Tomschik M, Widhalm G, Rössler K, Marosi C, Wöhrer A, Hainfellner JA, Oberndorfer S. Hainfellner A, et al. Among authors: dieckmann k. J Neurooncol. 2024 Nov;170(2):407-418. doi: 10.1007/s11060-024-04808-x. Epub 2024 Aug 27. J Neurooncol. 2024. PMID: 39192069 Free PMC article.
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases.
Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, Mair MJ, Starzer AM, Forstner H, Rottenmanner B, Aretin MB, Dieckmann K, Bago-Horvath Z, Haslacher H, Widhalm G, Ilhan-Mutlu A, Minichsdorfer C, Fuereder T, Szekeres T, Oehler L, Gruenberger B, Pfeiler G, Singer C, Weltermann A, Berchtold L, Preusser M. Bartsch R, et al. Among authors: dieckmann k. Neuro Oncol. 2024 Jul 4:noae123. doi: 10.1093/neuonc/noae123. Online ahead of print. Neuro Oncol. 2024. PMID: 38963808
567 results